BioSpace News Archive

GNC Holdings Inc. reminded stockholders to vote in advance of the Special Meeting of Stockholders scheduled to reconvene on Wednesday, May 9, 2018 (the “Special Meeting”).

CytoSorbents Corporation will report Q1 2018 financial results after the market close on Tuesday, May 8, 2018.

REGENXBIO Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-121.

Realm Therapeutics plc announces it has confidentially submitted a registration statement to the United States Securities and Exchange Commission (SEC) in connection with a proposed listing of American Depositary Shares (ADSs) representing the Company’s ordinary shares on the Nasdaq Global Market (Nasdaq).

PDL BioPharma, Inc. announced that it will release its first quarter 2018 financial results for the period ended March 31, 2018, on Wednesday, May 9, 2018, after market close.

Medicenna Therapeutics Corp. announced that half the patients in the ongoing Phase 2b study of MDNA55 in recurrent glioblastoma (rGBM) have been recruited and the data to date demonstrate solid safety results and early signals of efficacy based on the findings of the Safety Review and Clinical Advisory Committees, comprised of key opinion leaders and study investigators.

HeartSciences announced that Peter W. Macfarlane has joined its board of clinical advisors.

Acceleron Pharma Inc. announced that senior management will participate in two upcoming healthcare investor conferences in May.

LivaNova PLC reported results for the quarter ended March 31, 2018.

Foundation Medicine, Inc. announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development.